• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by 60 Degrees Pharmaceuticals Inc.

    7/18/25 5:46:00 PM ET
    $SXTP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SXTP alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    60 Degrees Pharmaceuticals, Inc.

    (Name of Issuer)


    Common stock, par value $0.0001 per share

    (Title of Class of Securities)


    83006G203

    (CUSIP Number)


    07/15/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    83006G203


    1Names of Reporting Persons

    Mitchell P. Kopin
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    372,429.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    329,817.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    372,429.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.99 %
    12Type of Reporting Person (See Instructions)

    HC, IN


    SCHEDULE 13G

    CUSIP No.
    83006G203


    1Names of Reporting Persons

    Daniel B. Asher
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    372,429.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    329,817.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    372,429.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.99 %
    12Type of Reporting Person (See Instructions)

    HC, IN


    SCHEDULE 13G

    CUSIP No.
    83006G203


    1Names of Reporting Persons

    Intracoastal Capital LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    372,429.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    329,817.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    372,429.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.99 %
    12Type of Reporting Person (See Instructions)

    OO


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    60 Degrees Pharmaceuticals, Inc.
    (b)Address of issuer's principal executive offices:

    1025 Connecticut Avenue NW, Suite 1000, Washington, D.C. 20036
    Item 2. 
    (a)Name of person filing:

    This Schedule 13G is being filed on behalf of (i) Mitchell P. Kopin, an individual ("Mr. Kopin"), (ii) Daniel B. Asher, an individual ("Mr. Asher") and (iii) Intracoastal Capital LLC, a Delaware limited liability company ("Intracoastal" and together with Mr. Kopin and Mr. Asher, collectively the "Reporting Persons").
    (b)Address or principal business office or, if none, residence:

    The principal business office of Mr. Kopin and Intracoastal is 245 Palm Trail, Delray Beach, Florida 33483. The principal business office of Mr. Asher is 1011 Lake Street, Suite 311, Oak Park, Illinois 60301.
    (c)Citizenship:

    Mr. Kopin is a citizen of the United States of America. Mr. Asher is a citizen of the United States of America. Intracoastal is a Delaware limited liability company.
    (d)Title of class of securities:

    Common stock, par value $0.0001 per share
    (e)CUSIP No.:

    83006G203
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    (i) Immediately following the execution of the Securities Purchase Agreement with the Issuer on July 15, 2025 (the "SPA") (as disclosed in the Form 424B5 prospectus filed by the Issuer with the Securities and Exchange Commission on July 16, 2025), each of the Reporting Persons may have been deemed to have beneficial ownership of 163,472 shares of Common Stock, which consisted of (i) 162,000 shares of Common Stock to be issued to Intracoastal at the closing of the transaction contemplated by the SPA and (ii) 1,472 shares of Common Stock issuable upon exercise of a warrant to be issued to Intracoastal at the closing of the transaction contemplated by the SPA ("Intracoastal Warrant 1"), and all such shares of Common Stock represent beneficial ownership of approximately 9.99% of the Common Stock, based on (1) 1,472,891 shares of Common Stock outstanding as of July 2, 2025, as reported by the Issuer, plus (2) 162,000 shares of Common Stock to be issued to Intracoastal at the closing of the transaction contemplated by the SPA and (3) 1,472 shares of Common Stock issuable upon exercise of Intracoastal Warrant 1. The foregoing excludes (I) 362,844 shares of Common Stock issuable upon exercise of Intracoastal Warrant 1 because Intracoastal Warrant 1 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 1 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder's affiliates, and any other persons acting as a group together with the holder or any of the holder's affiliates, of more than 9.99% of the Common Stock, (II) 526,316 shares of Common Stock issuable upon exercise of a second warrant to be issued to Intracoastal at the closing of the transaction contemplated by the SPA ("Intracoastal Warrant 2") because Intracoastal Warrant 2 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 2 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder's affiliates, and any other persons acting as a group together with the holder or any of the holder's affiliates, of more than 9.99% of the Common Stock, (III) 526,316 shares of Common Stock issuable upon exercise of a third warrant to be issued to Intracoastal at the closing of the transaction contemplated by the SPA ("Intracoastal Warrant 3") because Intracoastal Warrant 3 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 3 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder's affiliates, and any other persons acting as a group together with the holder or any of the holder's affiliates, of more than 9.99% of the Common Stock, (IV) 167 shares of Common Stock issuable upon exercise of a warrant held by Intracoastal ("Intracoastal Warrant 4") because Intracoastal Warrant 4 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 4 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder's affiliates, and any other persons acting as a group together with the holder or any of the holder's affiliates, of more than 4.99% of the Common Stock, (V) 167 shares of Common Stock issuable upon exercise of a second warrant held by Intracoastal ("Intracoastal Warrant 5") because Intracoastal Warrant 5 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 5 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder's affiliates, and any other persons acting as a group together with the holder or any of the holder's affiliates, of more than 4.99% of the Common Stock, (VI) 167 shares of Common Stock issuable upon exercise of a third warrant held by Intracoastal ("Intracoastal Warrant 6") because Intracoastal Warrant 6 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 6 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder's affiliates, and any other persons acting as a group together with the holder or any of the holder's affiliates, of more than 4.99% of the Common Stock, (VII) 101,861 shares of Common Stock issuable upon exercise of a fourth warrant held by Intracoastal ("Intracoastal Warrant 7") because Intracoastal Warrant 7 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 7 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder's affiliates, and any other persons acting as a group together with the holder or any of the holder's affiliates, of more than 4.99% of the Common Stock and (VIII) 75,175 shares of Common Stock issuable upon exercise of a fifth warrant held by Intracoastal ("Intracoastal Warrant 8") because Intracoastal Warrant 8 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 8 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder's affiliates, and any other persons acting as a group together with the holder or any of the holder's affiliates, of more than 4.99% of the Common Stock. Without such blocker provisions, each of the Reporting Persons may have been deemed to have beneficial ownership of 1,756,485 shares of Common Stock. (ii) As of the close of business on July 18, 2025, each of the Reporting Persons may have been deemed to have beneficial ownership of 372,429 shares of Common Stock, which consisted of (i) 45,612 shares of Common Stock held by Intracoastal, (ii) 189,316 shares of Common Stock issuable upon exercise of Intracoastal Warrant 1 and (iii) 137,501 shares of Common Stock issuable upon exercise of Intracoastal Warrant 2, and all such shares of Common Stock represent beneficial ownership of approximately 9.99% of the Common Stock, based on (1) 1,472,891 shares of Common Stock outstanding as of July 2, 2025, as reported by the Issuer, plus (2) 1,753,314 shares of Common Stock issued at the closing of the transaction contemplated by the SPA, (3) 175,000 shares of Common Stock issued to Intracoastal upon exercise of Intracoastal Warrant 1, (4) 189,316 shares of Common Stock issuable upon exercise of Intracoastal Warrant 1 and (5) 137,501 shares of Common Stock issuable upon exercise of Intracoastal Warrant 2. The foregoing excludes (I) 388,815 shares of Common Stock issuable upon exercise of Intracoastal Warrant 2 because Intracoastal Warrant 2 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 2 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder's affiliates, and any other persons acting as a group together with the holder or any of the holder's affiliates, of more than 9.99% of the Common Stock, (II) 526,316 shares of Common Stock issuable upon exercise of Intracoastal Warrant 3 because Intracoastal Warrant 3 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 3 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder's affiliates, and any other persons acting as a group together with the holder or any of the holder's affiliates, of more than 9.99% of the Common Stock, (III) 167 shares of Common Stock issuable upon exercise of Intracoastal Warrant 4 because Intracoastal Warrant 4 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 4 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder's affiliates, and any other persons acting as a group together with the holder or any of the holder's affiliates, of more than 4.99% of the Common Stock, (IV) 167 shares of Common Stock issuable upon exercise of Intracoastal Warrant 5 because Intracoastal Warrant 5 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 5 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder's affiliates, and any other persons acting as a group together with the holder or any of the holder's affiliates, of more than 4.99% of the Common Stock, (V) 167 shares of Common Stock issuable upon exercise of Intracoastal Warrant 6 because Intracoastal Warrant 6 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 6 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder's affiliates, and any other persons acting as a group together with the holder or any of the holder's affiliates, of more than 4.99% of the Common Stock, (VI) 101,861 shares of Common Stock issuable upon exercise of Intracoastal Warrant 7 because Intracoastal Warrant 7 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 7 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder's affiliates, and any other persons acting as a group together with the holder or any of the holder's affiliates, of more than 4.99% of the Common Stock and (VII) 75,175 shares of Common Stock issuable upon exercise of Intracoastal Warrant 8 because Intracoastal Warrant 8 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 8 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder's affiliates, and any other persons acting as a group together with the holder or any of the holder's affiliates, of more than 4.99% of the Common Stock. Without such blocker provisions, each of the Reporting Persons may have been deemed to have beneficial ownership of 1,465,097 shares of Common Stock.
    (b)Percent of class:

    9.99%
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    0

     (ii) Shared power to vote or to direct the vote:

    372,429

     (iii) Sole power to dispose or to direct the disposition of:

    0

     (iv) Shared power to dispose or to direct the disposition of:

    329,817

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Mitchell P. Kopin
     
    Signature:/s/ Mitchell P. Kopin
    Name/Title:Mitchell P. Kopin
    Date:07/18/2025
     
    Daniel B. Asher
     
    Signature:/s/ Daniel B. Asher
    Name/Title:Daniel B. Asher
    Date:07/18/2025
     
    Intracoastal Capital LLC
     
    Signature:/s/ Mitchell P. Kopin
    Name/Title:Mitchell P. Kopin, Manager
    Date:07/18/2025
    Exhibit Information

    Exhibit 1 - Joint Filing Agreement

    Get the next $SXTP alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $SXTP

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $SXTP
    SEC Filings

    See more
    • SEC Form SCHEDULE 13G filed by 60 Degrees Pharmaceuticals Inc.

      SCHEDULE 13G - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Subject)

      7/18/25 5:46:00 PM ET
      $SXTP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • 60 Degrees Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

      8-K - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Filer)

      7/18/25 4:57:48 PM ET
      $SXTP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 424B4 filed by 60 Degrees Pharmaceuticals Inc.

      424B4 - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Filer)

      7/16/25 8:49:05 AM ET
      $SXTP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SXTP
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • 60 Degrees Pharmaceuticals and Tulane University Sign Research Agreement to Study Tafenoquine Against Lyme and Bartonella Bacteria

      Study will evaluate activity of tafenoquine against vector-borne pathogens, Borrelia (Lyme disease) and Bartonella in cell cultureBorrelia and Bartonella, together with Babesia, represent the "3Bs," pathogens most often present in individuals with tick-borne illness such as Lyme disease WASHINGTON, July 17, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP, SXTPW)) ("60 Degrees" or the "Company"), a pharmaceutical company focused on developing new medicines for infectious diseases, today announced its entry into a sponsored research agreement with Tulane University to evaluate activity of tafenoquine against the vector-borne bacteria, Borrelia (Lyme disease) and Barto

      7/17/25 8:01:10 AM ET
      $SXTP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • 60 Degrees Pharmaceuticals Announces Closing of up to $10 Million Public Offering

      WASHINGTON, July 16, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (the "Company" or "60 Degrees") (NASDAQ:SXTP, SXTPW)), a pharmaceutical company focused on developing new medicines for infectious diseases, today announced the closing of its previously announced public offering of 2,631,578 shares of the Company's common stock (or pre-funded warrants in lieu thereof) and accompanying Series A-1 warrants to purchase up to 2,631,578 shares of common stock and short-term Series A-2 warrants to purchase up to 2,631,578 shares of common stock, at a combined offering price of $1.90 per share of common stock (or per pre-funded warrant in lieu thereof) and accompanying warrants. The

      7/16/25 4:01:00 PM ET
      $SXTP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • 60 Degrees Pharmaceuticals Announces Pricing of Up to $10 Million Public Offering

      WASHINGTON, July 15, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (the "Company" or "60 Degrees") (NASDAQ:SXTP, SXTPW)), a pharmaceutical company focused on developing new medicines for infectious diseases, today announced the pricing of a public offering of 2,631,578 shares of the Company's common stock (or pre-funded warrants in lieu thereof) and accompanying Series A-1 warrants to purchase up to 2,631,578 shares of common stock and short-term Series A-2 warrants to purchase up to 2,631,578 shares of common stock, at a combined offering price of $1.90 per share of common stock (or per pre-funded warrant in lieu thereof) and accompanying warrants. The Series A-1 warrants wil

      7/15/25 9:10:00 AM ET
      $SXTP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SXTP
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Xu Cheryl bought $14,410 worth of shares (5,000 units at $2.88), increasing direct ownership by 46% to 15,816 units (SEC Form 4)

      4 - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Issuer)

      6/5/25 8:53:09 PM ET
      $SXTP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Xu Cheryl bought $21,400 worth of shares (13,000 units at $1.65), increasing direct ownership by 32% to 54,078 units (SEC Form 4)

      4 - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Issuer)

      12/18/24 8:35:59 PM ET
      $SXTP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President and CEO Dow Geoffrey S bought $89,755 worth of shares (73,951 units at $1.21), increasing direct ownership by 358% to 94,580 units (SEC Form 4)

      4 - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Issuer)

      12/9/24 5:07:49 PM ET
      $SXTP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SXTP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President and CEO Dow Geoffrey S was granted 4,376 shares, increasing direct ownership by 20% to 26,171 units (SEC Form 4)

      4 - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Issuer)

      6/9/25 5:23:56 PM ET
      $SXTP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Xu Cheryl bought $14,410 worth of shares (5,000 units at $2.88), increasing direct ownership by 46% to 15,816 units (SEC Form 4)

      4 - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Issuer)

      6/5/25 8:53:09 PM ET
      $SXTP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by President and CEO Dow Geoffrey S

      4 - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Issuer)

      1/24/25 4:52:30 PM ET
      $SXTP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SXTP
    Financials

    Live finance-specific insights

    See more
    • VSee Health and 60 Degrees Pharmaceuticals Interviews Aired on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

      ORLANDO, FL / ACCESSWIRE / December 2, 2024 / RedChip Companies aired interviews with VSee Health, Inc. (NASDAQ:VSEE) and 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV on November 30. Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:VSEE: https://www.redchip.com/assets/access/vsee_accessSXTP: https://www.redchip.com/assets/access/sxtp_accessIn an exclusive interview, Imo Aisiku, M.D., co-CEO and Chairman of VSee Health, appears on the RedChip Small Stocks Big Money™ show on Bloomberg TV to share insight into how VSee Health's differentiated so

      12/2/24 4:05:00 PM ET
      $SXTP
      $VSEE
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medical/Nursing Services
    • 60 Degrees Pharmaceuticals and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

      ORLANDO, FL / ACCESSWIRE / November 22, 2024 / RedChip Companies will air interviews with 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP) and Can-Fite BioPharma Ltd. (NYSE:CANF)(TASE:CANF) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, November 23, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:SXTP: https://www.redchip.com/assets/access/sxtp_accessCANF: https://www.redchip.com/assets/access/canf_accessIn an exclusive interview, Geoffrey Dow, CEO and President of 60 Degrees Pharmaceuticals, appears on the RedChip Small Stocks Big Money™ show on

      11/22/24 9:00:00 AM ET
      $CANF
      $SXTP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Genetic Technologies Limited and 60 Degrees Pharmaceuticals Interviews to Air on the RedChip Money Report® on Bloomberg TV

      MELBOURNE, Australia, Sept. 01, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited ((ASX: GTG, NASDAQ:GENE, "Company", "GTG")), a global leader in guideline driven genomics-based tests in health, wellness and serious disease is pleased to advise that RedChip Companies will air interviews with Genetic Technologies Limited (NASDAQ:GENE) and 60 Degrees Pharmaceuticals (60P) (NASDAQ:SXTP) on The RedChip Money Report®, a sponsored program on Bloomberg TV, this Saturday, September 2, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S. Access the interviews in their entirety at: •  Genetic Technologies (NASDAQ:GENE): https://www.redchip.com/

      9/1/23 10:00:00 AM ET
      $GENE
      $SXTP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations

    $SXTP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by 60 Degrees Pharmaceuticals Inc.

      SC 13G - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Subject)

      11/14/24 3:37:18 PM ET
      $SXTP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by 60 Degrees Pharmaceuticals Inc.

      SC 13G/A - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Subject)

      11/13/24 4:01:15 PM ET
      $SXTP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by 60 Degrees Pharmaceuticals Inc. (Amendment)

      SC 13G/A - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Subject)

      5/7/24 7:19:08 PM ET
      $SXTP
      Biotechnology: Pharmaceutical Preparations
      Health Care